Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04421560
Title Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute

central nervous system lymphoma


Ibrutinib + Pembrolizumab + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.